MIGS: Definition, Uses, and Clinical Overview

MIGS Introduction (What it is)

MIGS stands for minimally invasive glaucoma surgery.
It refers to a group of small-incision surgical procedures designed to help lower intraocular pressure (IOP).
MIGS is most commonly used for glaucoma, especially mild to moderate disease.
Many MIGS procedures are performed at the time of cataract surgery, though some are done on their own.

Why MIGS used (Purpose / benefits)

Glaucoma is an eye disease in which damage to the optic nerve (the nerve that carries visual information to the brain) is often associated with elevated IOP. IOP is influenced by how the eye makes and drains aqueous humor, the clear fluid inside the front part of the eye. When outflow is reduced, pressure can rise and contribute to optic nerve injury.

MIGS is used to reduce IOP and/or reduce reliance on glaucoma eye drops in selected patients. Compared with more traditional glaucoma surgeries (such as trabeculectomy or tube shunts), MIGS is designed to be less disruptive to eye tissues, often using an ab interno approach (from inside the eye) through a small corneal incision. This approach aims to preserve the conjunctiva (the thin tissue covering the white of the eye), which may matter for future procedures.

Potential benefits often discussed with MIGS include:

• IOP lowering appropriate for certain stages and types of glaucoma
• Medication burden reduction, which can help when drops are difficult to use, cause side effects, or are hard to afford
• Faster visual recovery in many cases compared with more invasive filtering surgery (varies by procedure and patient)
• A safety profile that is generally favorable relative to traditional filtering surgery, while recognizing that all eye surgery carries risk
• The ability to combine MIGS with cataract surgery in the same operating session for selected patients

The overall goal is not “vision correction” in the way glasses or refractive surgery work. Instead, MIGS is focused on pressure management to help slow glaucoma progression.

Indications (When ophthalmologists or optometrists use it)

Typical scenarios where MIGS may be considered include:

• Primary open-angle glaucoma (mild to moderate) where additional IOP lowering is desired
• Ocular hypertension (elevated IOP without confirmed optic nerve damage) in select surgical planning contexts (varies by clinician and case)
• Patients undergoing cataract surgery who also have glaucoma and may benefit from additional IOP control
• Individuals who are intolerant of glaucoma drops (redness, allergy, ocular surface irritation) or have difficulty with adherence
• A need to reduce the number of medications while maintaining acceptable IOP
• Certain cases of pseudoexfoliative or pigmentary glaucoma with an open angle (procedure selection varies by anatomy and surgeon preference)
• Patients in whom preserving the conjunctiva for potential future surgery is a priority

Optometrists often identify candidates through glaucoma evaluation and monitoring, then refer to an ophthalmologist (often a glaucoma specialist) for surgical assessment.

Contraindications / when it’s NOT ideal

MIGS is not a single operation, and suitability depends on the specific device or technique. In general, MIGS may be less suitable or not ideal in situations such as:

• Angle-closure glaucoma or narrow angles where access to the drainage angle is limited (unless angle anatomy is addressed and the approach is appropriate)
• Advanced glaucoma requiring very low target IOP that may be more reliably achieved with traditional filtering surgery (varies by clinician and case)
• Active uveitis (intraocular inflammation) or uncontrolled ocular inflammation
• Significant corneal opacity or poor view that prevents safe angle visualization during surgery
• Certain forms of neovascular glaucoma or severe secondary glaucomas where outflow pathways are markedly compromised
• Extensive angle scarring (peripheral anterior synechiae) that blocks access to the trabecular meshwork
• Situations where prior surgeries or conjunctival scarring make a specific MIGS option less suitable (device- and approach-dependent)
• Patients unable to participate in necessary postoperative follow-up (follow-up needs vary by procedure)

Because MIGS includes multiple techniques, contraindications should be interpreted as procedure-specific considerations, not blanket rules.

How it works (Mechanism / physiology)

MIGS procedures aim to lower IOP by improving aqueous humor outflow, reducing aqueous production, or creating an alternate drainage pathway. The most common physiologic target is the eye’s conventional outflow system, which includes:

• Trabecular meshwork (TM): a tissue at the drainage angle that provides resistance to outflow in many open-angle glaucomas
• Schlemm’s canal: a circular channel that collects aqueous from the TM
• Collector channels and episcleral veins: downstream pathways that return fluid to the bloodstream

Other MIGS approaches target:

• The suprachoroidal space (a potential space between layers of the eye wall) to enhance uveoscleral outflow (use depends on the current availability and risk profile of specific devices)
• The subconjunctival space to create a controlled bleb (a small fluid reservoir under the conjunctiva), conceptually closer to traditional filtering surgery but with smaller implants and different techniques

Mechanism of action (high-level)

• Trabecular bypass or TM modification: reduces resistance at the TM to enhance drainage into Schlemm’s canal
• Canal-based dilation/viscodilation: enlarges Schlemm’s canal and/or collector channel access to improve outflow
• Subconjunctival microshunts: diverts aqueous to a subconjunctival reservoir where it is absorbed
• Cyclodestructive approaches (sometimes grouped near the MIGS spectrum): reduce aqueous production by treating the ciliary body; classification varies by clinician and context

Onset, duration, and reversibility

• IOP effects may be seen soon after surgery, but stabilization can take time and depends on healing and inflammation control (varies by clinician and case).
• Longevity can vary; some procedures provide sustained benefit for years in selected patients, while others may diminish over time due to healing responses or disease progression.
• Reversibility depends on the technique. Some implants can be removed or revised, but the procedures are generally considered not fully reversible in the way a medication can be stopped.

MIGS Procedure overview (How it’s applied)

MIGS refers to surgical procedures rather than a medication or diagnostic test. While exact steps differ, a typical workflow looks like this:

1. Evaluation/exam
   – Comprehensive eye exam with glaucoma assessment: IOP measurement, optic nerve evaluation, visual field testing, and imaging as appropriate (such as OCT).
   – Gonioscopy (a lens-based exam to view the drainage angle) to assess angle anatomy and suitability for angle-based MIGS.
   – Discussion of goals (IOP reduction, medication reduction), alternatives, and the type of MIGS that matches anatomy and disease stage.

2. Preparation
   – Surgical planning, often coordinated with cataract surgery when present.
   – Preoperative measurements and review of current medications and general health (varies by clinic and surgical center).
   – Use of anesthesia appropriate for outpatient eye surgery (commonly topical and/or local anesthesia with sedation; varies by case).

3. Intervention/testing
   – A small corneal incision is commonly used to access the anterior chamber.
   – The surgeon uses a microscope and specialized viewing techniques to reach the angle and perform the selected MIGS method (implant placement, tissue incision/excision, canal dilation, or microshunt placement).

4. Immediate checks
   – IOP and wound integrity are checked.
   – Early monitoring focuses on inflammation, bleeding in the front of the eye (if present), and clarity of the cornea.

5. Follow-up
   – Postoperative visits assess IOP, healing, and the need for continued glaucoma medications.
   – Anti-inflammatory and/or antibiotic drops are commonly used after surgery, with regimens varying by surgeon and procedure.

This overview is intentionally general; MIGS is a category with different techniques, and clinical protocols vary.

Types / variations

MIGS is best understood as a family of approaches, often grouped by the outflow pathway they target.

Trabecular meshwork / Schlemm’s canal–based MIGS (angle-based)

These aim to improve conventional outflow with minimal disturbance to conjunctiva.

• Trabecular micro-bypass stents: small implants that create a pathway through the TM into Schlemm’s canal.
• Goniotomy / trabeculotomy-style procedures: involve opening or removing part of the TM to reduce resistance. Device-assisted and non-device variations exist.
• Canaloplasty/viscodilation approaches: dilate Schlemm’s canal (and sometimes collector channel access) to enhance outflow. Some methods use microcatheters or specialized handpieces.

These procedures are commonly considered for open-angle glaucoma and are frequently combined with cataract surgery.

Subconjunctival MIGS (bleb-forming approaches)

These create an alternate drainage route to the subconjunctival space.

• Gel stents and microshunts: small tubes designed to channel aqueous to a subconjunctival reservoir.

Because these create a bleb, they may require more bleb-focused postoperative management, and the risk profile can overlap in some ways with traditional filtering surgeries (though techniques and devices differ).

Suprachoroidal approaches (uveoscleral enhancement)

These aim to increase drainage through the suprachoroidal pathway. The availability and use of suprachoroidal devices have changed over time, and clinical adoption depends on the safety profile and regulatory status of specific products.

Cyclophotocoagulation and related procedures

Some clinicians discuss less invasive cyclodestructive procedures alongside MIGS concepts because they can be performed with relatively small incisions or non-incisional laser delivery. Classification varies, and these are not strictly “outflow” procedures.

Standalone vs combined procedures

• Combined MIGS + cataract surgery: often chosen when cataract is present and both visual improvement and IOP management are goals.
• Standalone MIGS: performed without cataract surgery, depending on technique, anatomy, and clinical goals.

Pros and cons

Pros:

• Often smaller incisions and less tissue disruption than traditional glaucoma filtration surgery
• Can be combined with cataract surgery in appropriate cases
• May lower IOP and/or reduce medication burden for selected glaucoma patients
• Typically short operative time relative to more complex filtering surgery (varies by procedure)
• Many approaches preserve conjunctiva, which can matter for future surgery planning
• A range of options allows tailoring to anatomy (angle-based vs subconjunctival, implant vs no implant)

Cons:

• IOP lowering may be modest compared with trabeculectomy or tube shunts, especially in advanced glaucoma (varies by clinician and case)
• Not all glaucoma types or angle anatomies are suitable
• Surgical risks still exist, including inflammation, bleeding in the anterior chamber, infection, pressure spikes or hypotony (risk depends on procedure)
• Outcomes can be influenced by healing response and disease progression
• Some procedures involve implants, introducing device-specific considerations (positioning, obstruction, long-term behavior varies by material and manufacturer)
• Some patients still need ongoing drops or additional procedures after MIGS

Aftercare & longevity

Aftercare depends on the specific MIGS type and whether it was combined with cataract surgery. In general, clinicians monitor:

• IOP trends over time rather than a single reading
• Signs of inflammation and the eye’s healing response
• The health of the cornea and anterior chamber
• For bleb-forming procedures, the appearance and function of the bleb
• Ongoing evaluation of glaucoma status using optic nerve exam, OCT, and visual fields as appropriate

Longevity and outcomes are influenced by multiple factors:

• Baseline glaucoma severity and the target IOP needed to slow progression
• Angle anatomy and the condition of the outflow system
• Adherence to follow-up, since early healing can affect long-term performance
• Ocular surface health and tolerance of postoperative drops
• Coexisting eye conditions (for example, uveitis, severe dry eye, retinal disease)
• Procedure selection and surgeon technique, which can vary by clinician and case
• For implants, device design and material properties (varies by material and manufacturer)

Some patients experience sustained benefit, while others may require additional medications, laser, or further surgery over time.

Alternatives / comparisons

MIGS sits between medical therapy/laser and more traditional incisional glaucoma surgery. Common alternatives or related options include:

• Observation/monitoring: appropriate for some patients with stable findings or low risk of progression, with regular exams and testing.
• Glaucoma medications (eye drops): often first-line for many types of glaucoma; effective for many patients but can be limited by side effects, cost, and adherence challenges.
• Laser trabeculoplasty (e.g., SLT): a non-incisional laser treatment targeting the trabecular meshwork to improve outflow in open-angle glaucoma. It can be used before or after MIGS depending on the case.
• Traditional filtering surgery (trabeculectomy): often used when a lower target IOP is required; it can provide substantial IOP lowering but generally carries more intensive aftercare and a different risk profile.
• Glaucoma drainage devices (tube shunts): often used in complex or advanced cases, including some secondary glaucomas or eyes with prior surgery.
• Cyclodestructive procedures: reduce aqueous production and may be considered in specific scenarios; technique and intensity vary.

A simple way to compare is by typical goals and tradeoffs: MIGS may be considered when clinicians want additional IOP control with a less invasive approach, while traditional filtration/tube surgery may be favored when the clinical need is very low IOP or when other methods are insufficient. The “right” option is highly individualized.

MIGS Common questions (FAQ)

Q: Is MIGS the same as cataract surgery?
No. MIGS is glaucoma surgery intended to lower IOP, while cataract surgery removes a cloudy natural lens. MIGS is often performed at the same time as cataract surgery in patients who have both cataract and glaucoma, but they are distinct procedures.

Q: Does MIGS cure glaucoma?
Glaucoma is generally considered a chronic condition. MIGS aims to help manage IOP and reduce risk of progression, but it does not restore optic nerve damage that has already occurred. Ongoing monitoring remains important after any glaucoma treatment.

Q: Will I still need glaucoma eye drops after MIGS?
Some people can reduce the number of drops, and some continue the same medications. The result depends on the MIGS type, baseline IOP, glaucoma severity, and healing response. Medication plans are adjusted based on postoperative IOP and stability over time.

Q: Does MIGS hurt?
Most MIGS procedures are performed with anesthesia commonly used for outpatient eye surgery. Patients may feel pressure or mild discomfort rather than sharp pain during the procedure, though experiences vary. Temporary irritation after surgery can occur, especially if combined with cataract surgery.

Q: How long is recovery after MIGS?
Recovery varies by the specific procedure and whether cataract surgery was done at the same time. Many patients resume normal routines relatively quickly, but vision can fluctuate during early healing. Follow-up visits help track IOP and detect inflammation or pressure changes.

Q: How long do MIGS results last?
Longevity varies by clinician and case. Some patients have durable IOP reduction, while others may see diminishing effect over time due to healing responses or disease progression. Additional treatments (drops, laser, or further surgery) may still be needed later.

Q: Is MIGS safe?
MIGS is designed to reduce tissue disruption compared with more invasive glaucoma surgery, but it is still surgery and carries risks. The risk profile depends on the specific technique (angle-based vs bleb-forming), the eye’s anatomy, and coexisting conditions. Safety discussions are typically individualized and procedure-specific.

Q: Can I drive or use screens after MIGS?
Immediately after surgery, vision may be blurred and the eye may be light sensitive, so activities like driving may not be appropriate right away. Screen use is often possible as comfort allows, but dryness and irritation can affect tolerance. Timing varies by procedure and individual recovery.

Q: How much does MIGS cost?
Cost depends on the country, insurance coverage, surgical setting, and the specific device or technique used. Some MIGS implants add device-related expenses. The out-of-pocket portion varies widely and is best clarified with the surgical center and insurer.

Q: Who is a good candidate for MIGS?
Candidacy is based on glaucoma type and stage, angle anatomy, current IOP and medications, and whether cataract surgery is planned. Many MIGS procedures are designed for open-angle glaucoma, especially mild to moderate disease. Final selection depends on clinician assessment and patient-specific goals and constraints.